Cell Immunotherapy Company Enlivex Merges With Nasdaq-Listed Bioblast, Raises $5.3 Million
28.03.19 | Lilach Baumer
This site uses cookies to ensure the best viewing experience for our readers.
Bioblast
1 story about Bioblast
Tag does not exist. Please try again.